Mounjaro Versus Wegovy: Understanding the Core Mechanisms
The fundamental difference when comparing Mounjaro versus Wegovy lies in their active ingredients and receptor targeting mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to reduce appetite and promote satiety after meals. Mounjaro contains tirzepatide, which functions as a dual receptor agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously.
This dual-action approach of Mounjaro may offer different metabolic effects compared to Wegovy's single GLP-1 targeting, though both treatments require clinical assessment to determine suitability. When evaluating Wegovy vs Mounjaro, your prescriber considers your individual health profile, medical history, and treatment goals. Both prescription-only medicines work alongside lifestyle modifications and represent clinically proven approaches to weight management through different but related pathways.
Pricing and Value Comparison for Mounjaro Versus Wegovy
EverydayMeds offers transparent pricing for both treatments, allowing direct cost comparison when choosing between Wegovy vs Mounjaro options. Wegovy pricing starts with 0.25mg pens at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99 per pen. New customers apply discount code FIRST40 at checkout, whilst returning customers use code DOSE25 to access these competitive prices.
Mounjaro follows its own pricing structure with different dosing increments, starting at 2.5mg and escalating through 5mg, 7.5mg, 10mg, 12.5mg, to the maximum 15mg maintenance dose. Both treatments offer bundle options for convenience, including our popular Intro Duo bundles and 3-month stability packages. The choice between Mounjaro versus Wegovy often involves considering both clinical suitability and long-term cost implications during your weight management journey.
Clinical Evidence Supporting Wegovy vs Mounjaro Decisions
Wegovy's clinical foundation rests on the comprehensive STEP trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks when used alongside diet and exercise modifications. The recent SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events, as reported by Wilding et al., NEJM, 2021, highlighting Wegovy's broader health benefits beyond weight management.
Mounjaro's clinical evidence stems from the SURMOUNT trial series, showing its own significant efficacy profile in weight management applications. When comparing Mounjaro versus Wegovy clinical data, it's important to note that direct head-to-head trials have not been conducted, and different trial designs, populations, and endpoints make percentage comparisons inappropriate. Your prescriber evaluates which treatment's evidence profile aligns better with your individual health circumstances and treatment objectives.
How Wegovy Works in Your Weight Management Programme
Wegovy functions as a GLP-1 receptor agonist, essentially mimicking the action of incretin hormones that your intestines naturally produce after eating. Once injected weekly, semaglutide activates GLP-1 receptors in your brain's appetite control centres, particularly in the hypothalamus, reducing hunger signals and increasing feelings of fullness. The treatment also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged satiety after smaller meal portions. Additionally, Wegovy may help reduce food cravings and the reward value of high-calorie foods by influencing neural pathways associated with food preference. This multi-faceted approach supports sustainable weight management when combined with reduced-calorie eating patterns and increased physical activity. The weekly injection schedule using the FlexTouch pen system provides consistent medication levels throughout your treatment programme.
Streamlined Ordering Process for Both Treatments
EverydayMeds simplifies access to both Wegovy and Mounjaro through our comprehensive online clinical assessment, which takes approximately three minutes to complete and covers your medical history, current medications, and weight management goals. Following submission, our qualified prescribers review your assessment within three working days (or 24 hours with express service), ensuring appropriate clinical oversight for these prescription-only medicines. Once approved, your treatment ships via next-day delivery using specialised cold-chain logistics to maintain proper temperature throughout transit. Our GPhC-registered pharmacy (#9012878) handles all aspects of storage, dispensing, and delivery, meeting strict pharmaceutical standards for these temperature-sensitive medications. You receive comprehensive information about injection technique, dose escalation schedules, and ongoing support throughout your treatment journey with either Mounjaro or Wegovy.
Storage and Practical Considerations for Daily Use
Storage requirements present a notable practical difference when comparing Mounjaro versus Wegovy for long-term treatment planning. Wegovy pens require refrigeration at 2-8°C before first use but offer significant travel flexibility with up to six weeks of room temperature storage below 30°C once removed from the fridge. Mounjaro pens also need refrigeration but provide only 21 days of room temperature tolerance, which may influence your choice if you travel frequently or prefer flexible storage options. Both treatments use similar injection pen systems with pre-filled doses, though the escalation schedules differ significantly - Wegovy progresses through five dose levels over 16 weeks, whilst Mounjaro typically follows a six-dose escalation pattern. The weekly injection schedule remains consistent for both treatments, with most patients choosing the same day each week for routine establishment. Understanding these practical aspects helps inform your decision between Wegovy vs Mounjaro based on lifestyle compatibility and convenience preferences.
Dual-Agonist Innovation Versus Established GLP-1 Therapy
The choice between Mounjaro versus Wegovy often centres on comparing established single-target therapy against innovative dual-receptor mechanisms. Wegovy represents the refinement of GLP-1 agonist technology with extensive real-world usage data and comprehensive safety profiles developed over several years of clinical application. The treatment's cardiovascular benefits, demonstrated in the SELECT trial, add an additional dimension beyond weight management for patients with relevant risk factors.
Mounjaro's dual GIP/GLP-1 agonist approach represents a newer therapeutic strategy that may offer different metabolic advantages through its broader receptor targeting. Some patients may respond better to dual-pathway stimulation, whilst others achieve optimal results with focused GLP-1 activation. Your prescriber considers factors including your metabolic profile, previous treatment responses, and individual health goals when recommending between these approaches for your weight management programme.
Making Your Treatment Decision with Expert Support
Both Wegovy and Mounjaro are available through EverydayMeds, ensuring you can access either treatment based on clinical suitability rather than availability constraints. Our clinical team provides ongoing support regardless of which prescription-only medicine your prescriber recommends, with comprehensive guidance on injection technique, side effect management, and treatment optimisation. You can begin your clinical assessment today using discount code FIRST40 for new customers, with both treatments available for next-day delivery once prescribed. Visit https://everydaymeds.co.uk/collections/weight-loss to start your assessment and discover which treatment aligns with your weight management goals. Our GPhC-registered pharmacy (#9012878) ensures you receive authentic, properly stored medication with full clinical oversight throughout your treatment journey. Remember that successful weight management requires commitment to lifestyle changes alongside whichever treatment your prescriber recommends for optimal results.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026